Craig Thomas Wallington-Gates

Flinders University

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (18)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (14)

Nirmal Robinson

University of South Australia

AUSTRALIA

View details

John Toubia

University of South Australia

AUSTRALIA

View details

MANJUN LI

University of South Australia

AUSTRALIA

View details

Tim Chataway

Flinders University

AUSTRALIA

View details

Clive Prestidge

University of South Australia

AUSTRALIA

View details

Melinda Tea

University of South Australia

AUSTRALIA

View details

Brett Stringer

Flinders University

AUSTRALIA

View details

Hang Quach

University of Melbourne

AUSTRALIA

View details

Gregory Goodall

University of South Australia

AUSTRALIA

View details

Giles Best

Flinders University

AUSTRALIA

View details

Darren J Creek

MONASH UNIVERSITY

AUSTRALIA

View details

Jason Powell

University of South Australia

AUSTRALIA

View details

Stuart Pitson

University of South Australia

AUSTRALIA

View details

Melissa Pitman

Senior Lecturer, Lab Head

University of Adelaide

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Craig Thomas Wallington-Gates

Research Interests

Explore related searches

Contact this professor

Articles (18)

The instrumental role of lipids in governing the sensitivity of multiple myeloma to ferroptosis

Novel (1S,3R)-RSL3-Encapsulated Polyunsaturated Fatty Acid Rich Liposomes Sensitise Multiple Myeloma Cells to Ferroptosis-Mediated Cell Death

Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)

Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Circular RNAs drive oncogenic chromosomal translocations within the MLL recombinome in leukemia

A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies

A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19-02 BELACARD STUDY.

Prognostic and predictive biomarker developments in multiple myeloma

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Collaborators (14)

Nirmal Robinson

John Toubia

MANJUN LI

Tim Chataway

Clive Prestidge

Melinda Tea

Brett Stringer

Hang Quach

Gregory Goodall

Giles Best

Darren J Creek

Jason Powell

Stuart Pitson

Melissa Pitman

Make your next move.